NVDA

174.93

+1.05%↑

AVGO.US

311.04

+0.93%↑

366.81

+12%↑

ORCL

144.95

-0.94%↓

CSCO

78.06

+1.46%↑

NVDA

174.93

+1.05%↑

AVGO.US

311.04

+0.93%↑

366.81

+12%↑

ORCL

144.95

-0.94%↓

CSCO

78.06

+1.46%↑

NVDA

174.93

+1.05%↑

AVGO.US

311.04

+0.93%↑

366.81

+12%↑

ORCL

144.95

-0.94%↓

CSCO

78.06

+1.46%↑

NVDA

174.93

+1.05%↑

AVGO.US

311.04

+0.93%↑

366.81

+12%↑

ORCL

144.95

-0.94%↓

CSCO

78.06

+1.46%↑

NVDA

174.93

+1.05%↑

AVGO.US

311.04

+0.93%↑

366.81

+12%↑

ORCL

144.95

-0.94%↓

CSCO

78.06

+1.46%↑

Home・Akciju saraksts・CEVA Inc

CEVA Inc

Atvērts

SektorsTehnoloģijas

19.29 5.93

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

18.26

Max

19.57

Galvenie mērījumi
By Trading Economics
Ienākumi	3.3M 754K
Pārdošana	2.9M 31M
Peļņas marža	2.41
Darbinieki	424
EBITDA	1.8M 2.1M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+67.34% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 6. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-90M 523M
Iepriekšējā atvēršanas cena	13.36
Iepriekšējā slēgšanas cena	19.29

Ziņu noskaņojums

By Acuity

24%

76%

53 / 375 Rangs Technology

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

20.24 / 26.185 Atbalsts un pretestība

CEVA Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 31. marts 23:31 UTC

Karstas akcijas

Stocks to Watch: Nike, RH, NCino

2026. g. 31. marts 22:35 UTC

Peļņas

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

2026. g. 1. apr. 00:00 UTC

Iegādes, apvienošanās, pārņemšana

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

2026. g. 31. marts 23:50 UTC

Iegādes, apvienošanās, pārņemšana

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

2026. g. 31. marts 23:43 UTC

Tirgus saruna

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

2026. g. 31. marts 23:33 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

2026. g. 31. marts 23:21 UTC

Peļņas

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

2026. g. 31. marts 23:14 UTC

Tirgus saruna

Peļņas

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

2026. g. 31. marts 23:12 UTC

Tirgus saruna

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

2026. g. 31. marts 22:36 UTC

Peļņas

China Vanke 2025 Loss Widens >000002.SZ

2026. g. 31. marts 22:36 UTC

Peļņas

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

2026. g. 31. marts 22:36 UTC

Peļņas

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

2026. g. 31. marts 22:36 UTC

Peļņas

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

2026. g. 31. marts 22:36 UTC

Peļņas

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

2026. g. 31. marts 21:46 UTC

Iegādes, apvienošanās, pārņemšana

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

2026. g. 31. marts 21:36 UTC

Tirgus saruna

West African Resources's Costs Higher Than Bull Expected -- Market Talk

2026. g. 31. marts 21:35 UTC

Peļņas

Nike Expects China Sales Down 20% in 4Q, CFO Says

2026. g. 31. marts 21:35 UTC

Peļņas

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

2026. g. 31. marts 21:35 UTC

Peļņas

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

2026. g. 31. marts 21:33 UTC

Iegādes, apvienošanās, pārņemšana

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

2026. g. 31. marts 21:33 UTC

Peļņas

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

2026. g. 31. marts 21:32 UTC

Peļņas

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

2026. g. 31. marts 21:28 UTC

Peļņas

Nike Expects to End 4Q With Elevated Inventory, CFO Says

2026. g. 31. marts 21:26 UTC

Peļņas

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

2026. g. 31. marts 21:25 UTC

Peļņas

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

2026. g. 31. marts 21:24 UTC

Tirgus saruna

Peļņas

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

2026. g. 31. marts 21:22 UTC

Peļņas

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

2026. g. 31. marts 21:22 UTC

Peļņas

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

2026. g. 31. marts 21:21 UTC

Peļņas

Nike's Digital Channel Still Too Promotional, CFO Says

2026. g. 31. marts 21:20 UTC

Peļņas

Nike CEO: Converse Remains Important to Portfolio

Salīdzinājums

Cenas izmaiņa

CEVA Inc Prognoze

Cenas mērķis

By TipRanks

67.34% augšup

Prognoze 12 mēnešiem

Vidējais 28.8 USD 67.34%

Augstākais 35 USD

Zemākais 22 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi CEVA Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

5 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 5 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam CEVA Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

20.24 / 26.185Atbalsts un pretestība

Recent bearish events outweigh bullish events.

All events are bearish.

Recent bearish events outweigh bullish events.

Noskaņojums

By Acuity

53 / 375 Rangs Tehnoloģijas

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par CEVA Inc

CEVA, Inc. provides silicon and software IP solutions to semiconductor and original equipment manufacturer (OEM) companies worldwide. Its 5G mobile and infrastructure products include Ceva-XC vector digital signal processors (DSPs) for 5G handsets, 5G RAN, and general-purpose baseband processing; PentaG-RAN, an open ran platform for base station and radio; and PentaG2 - 5G NR modem platform for UE, as well as for non-handset 5G vertical markets, such as fixed wireless access, industry 4.0, robotics, and AR/VR devices. The company's wireless IoT products comprise RivieraWaves' Bluetooth 5dual mode and low energy platforms, RivieraWaves' Wi-Fi platforms, ultra-wide band platforms, and Cellular IoT and RedCap platforms, as well as sense and inference processors and platforms consist of NeuPro-M neural processing unit (NPU) family; SensPro2 sensor hub AI platforms addressing imaging, vision, powertrain, and applications, including DSP processors, AI accelerators, and a software portfolio; and Ceva-BX1 and Ceva-BX2 audio AI DSPs. Its sensing and audio software comprise RealSpace spatial audio software package; WhisPro speech recognition; ClearVox, a voice front-end software package for voice-enabled devices; and CDNN, a neural network graph compiler that enables AI developers to automatically compile, optimize, and run pre-trained networks onto embedded devices. The company's application software IP are licensed primarily to OEMs who embed it in their system on chip designs. It delivers AI DSPs and NPUs in the form of a hardware description language definition; and offers development platforms, software development kits, and software debug tools, which facilitate system design, debug, and software development. The company licenses its technology through a direct sales force. CEVA, Inc. was formerly known as ParthusCeva, Inc. and changed its name to CEVA, Inc. in December 2003. The company was incorporated in 1999 and is headquartered in Rockville, Maryland.